Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study

Area of Science:

• Psychiatry
• Clinical Trials Methodology
• Pharmacoeconomics

Background:

• Randomized controlled trials (RCTs) are the gold standard but may not reflect real-world psychiatric treatment complexity.
• Schizophrenia treatment strategies, particularly first-generation vs. second-generation antipsychotics, present challenges due to patient heterogeneity and physician preferences.
• Existing study designs like the Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study (COST study) are patient-oriented but physician-dependent, while RCTs can be less clinically relevant.

Purpose of the Study:

• To develop and evaluate a novel clinical trial design that bridges the gap between RCTs and patient-oriented clinical studies.
• To create a more adaptable and clinically relevant research framework for comparing complex treatment strategies in schizophrenia.
• To address the limitations of current study designs in capturing the nuances of psychiatric treatment decisions.

Main Methods:

• A two-step randomization process was implemented: first, randomizing pairs of first-generation and second-generation antipsychotics, and second, allowing investigator-guided selection of the most appropriate pair for the patient.
• The design was tested in the Neuroleptic Strategy Study, comparing efficacy and safety of first-generation antipsychotics (haloperidol, flupentixol) versus second-generation antipsychotics (olanzapine, aripiprazole, quetiapine) in schizophrenia patients.
• Investigated theoretical properties of the design, including feasibility, randomization process, data collection (investigator and patient responses), drug logistics, and analysis of physician preferences.

Main Results:

• The feasibility of the proposed novel trial design was successfully demonstrated within the Neuroleptic Strategy Study.
• All components of the design, including randomization, data collection, and drug management, were effectively implemented.
• The study provided insights into the theoretical properties of the design and analyzed physician preferences in drug selection for schizophrenia patients.

Conclusions:

• The developed patient-oriented randomization design is feasible and demonstrates theoretical advantages for psychiatric research.
• This innovative design can be generalized to other complex treatment areas characterized by significant patient-drug interaction heterogeneity.
• The approach offers a valuable intermediate pathway, combining the rigor of RCTs with the clinical relevance of observational studies for schizophrenia treatment research.